Dipeptidyl peptidase-4 (DPP-4) inhibitors, including linagliptin, sitagliptin, and vildagliptin (V), are class of hypoglycemic agents used for treating type II diabetes through inhibition of glucagon-like peptide-1 (GLP-1) degradation [7]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.